Name (Synonyms) | Correlation | |
---|---|---|
drug264 | COVID-19 swap test PCR Wiki | 0.50 |
drug1514 | allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Wiki | 0.50 |
drug707 | Intravenous saline injection (Placebo) Wiki | 0.50 |
drug425 | Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki | 0.50 |
drug922 | Observation Wiki | 0.50 |
drug171 | Best Practice Wiki | 0.50 |
drug1402 | Tocilizumab Wiki | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
D020521 | Stroke NIH | 0.89 |
D009422 | Nervous System Diseases NIH | 0.50 |
D012640 | Seizures NIH | 0.50 |
D003072 | Cognition Disorders NIH | 0.50 |
D004827 | Epilepsy NIH | 0.50 |
D060825 | Cognitive Dysfunction NIH | 0.35 |
D007676 | Kidney Failure, Chronic NIH | 0.29 |
D003324 | Coronary Artery Disease NIH | 0.29 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.25 |
D008173 | Lung Diseases, Obstructive NIH | 0.20 |
D009369 | Neoplasms, NIH | 0.14 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001268 | Mental deterioration HPO | 0.35 |
HP:0001250 | Seizure HPO | 0.35 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.29 |
HP:0006510 | Chronic obstructive pulmonary disease HPO | 0.29 |
HP:0006536 | Obstructive lung disease HPO | 0.22 |
HP:0002664 | Neoplasm HPO | 0.15 |
There are 4 clinical trials
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsThe Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).
COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.
Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 3 month after start lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 3 month after start lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 3 month after start lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 3 month after start lockdownDescription: Patient-reported global rating of physical activity engagement and upper limb use in daily life
Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use) Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities
Measure: Fatigue Severity Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Depression and anxiety
Measure: Hospital Anxiety and Depression Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Assesses cognitive functions
Measure: Montreal Cognitive Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account
Measure: Functional Ambulation Categories Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Gait speed and cadence
Measure: Ten-Meter Walk Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs
Measure: Rivermead Mobility Index Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks
Measure: Activities-specific Balance Confidence Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper and lower limb motor function
Measure: Fugl-Meyer Motor Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper limb capacity
Measure: Action Research Arm Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Global disability
Measure: modified Rankin Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Neurological impairments
Measure: National Institutes of Health Stroke Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months